alexa Acute Demyelinating Polyneuropathy Caused by Nivolumab
ISSN: 2167-7182

Journal of Gerontology & Geriatric Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Letter to Editor

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer

Butt Sabeeh-Ur-Rehman1* and Shah Bhaumik2

1Department of Neurology, Ballarat Base Hospital, Ballarat, Victoria, Australia

2Department of Medical Oncology, Ballarat Base Hospital, Ballarat, Victoria, Australia

*Corresponding Author:
Butt Sabeeh-Ur-Rehman
Department of Neurology
Ballarat Base Hospital
Drummond Street North, Ballarat Central
VIC, 3350, Australia
Tel: 61353204000
E-mail: [email protected]

Received Date: March 14, 2016; Accepted Date: April 19, 2016; Published Date: May 19, 2016

Citation: Butt SUR, Bhaumik S (2016) Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer. J Gerontol Geriatr Res 5:302. doi:10.4172/2167-7182.1000302

Copyright: © 2016 Butt SUR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Immune checkpoint inhibitors include programmed cell death-1 receptor inhibitors (PD-1), programmed cell death ligand-1 inhibitors and CTLA-4 inhibitors and are novel treatment against certain cancers like non-small cell lung cancer (NSCLC), melanoma and renal cell cancer. They act by boosting the immune response against cancer cells and have improved the prognosis of patients with these cancers significantly shifting the treatment paradigm.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords